Use este identificador para citar ou linkar para este item:
http://www.repositorio.ufop.br/jspui/handle/123456789/13831
Título: | Liposomal formulation of ChimeraT, a multiple T-cell epitope-containing recombinant protein, is a candidate vaccine for human Visceral Leishmaniasis. |
Autor(es): | Lage, Daniela Pagliara Ribeiro, Patrícia Aparecida Fernandes Dias, Daniel Silva Mendonça, Débora Vasconcelos Costa Ramos, Fernanda Fonseca Carvalho, Lívia Mendes Steiner, Bethina Trevisol Tavares, Grasiele de Sousa Vieira Martins, Vivian Tamietti Machado, Amanda Sanchez Silva, João Augusto Oliveira da Santos, Thaís Teodoro de Oliveira Freitas, Camila Simões de Oliveira, Jamil Silvano de Roatt, Bruno Mendes Ávila, Ricardo Andrez Machado de Humbert, Maria Victoria Christodoulides, Myron Coelho, Eduardo Antônio Ferraz |
Palavras-chave: | Saponin Th1-type immunity |
Data do documento: | 2020 |
Referência: | LAGE, D. P. et al. Liposomal formulation of ChimeraT, a multiple T-cell epitope-containing recombinant protein, is a candidate vaccine for human Visceral Leishmaniasis. Vaccines, v. 8, n. 2, artigo 289, jun. 2020. Disponível em: <https://www.mdpi.com/2076-393X/8/2/289>. Acesso em: 10 jun. 2021. |
Resumo: | Background: Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity of ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into a human-compatible liposome formulation. Methods: BALB/c mice were immunized subcutaneously with ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline and immune responses examined in vitro and in vivo. Results: Immunization with the ChimeraT/liposome formulation induced a polarized Th1-type response and significant protection against L. infantum infection. ChimeraT/liposome vaccine stimulated significantly high levels of interferon (IFN)-γ, interleukin (IL)-12, and granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines by both CD4 and CD8 T-cells, with correspondingly lower levels of IL-4 and IL-10 cytokines. Induced antibodies were predominantly IgG2a isotype, and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide (NO). Furthermore, we examined a small number of treated VL patients and found higher levels of circulating anti-ChimeraT protein IgG2 antibodies, compared to IgG1 levels. Conclusions: Overall, the liposomal formulation of ChimeraT induced a protective Th1-type immune response and thus could be considered in future studies as a vaccine candidate against human VL. |
URI: | http://www.repositorio.ufop.br/jspui/handle/123456789/13831 |
DOI: | https://doi.org/10.3390/vaccines8020289 |
ISSN: | 2076-393X |
Licença: | This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Fonte: o PDF do artigo. |
Aparece nas coleções: | DECBI - Artigos publicados em periódicos |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
ARTIGO_LiposomalFormulationChimera.pdf | 2,64 MB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.